1. Search Result
Search Result
Results for "

beagle

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

2

Peptides

5

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B2209B
    Hydroxocobalamin acetate
    3 Publications Verification

    Vitamin B12a acetate

    NO Synthase Cardiovascular Disease Metabolic Disease
    Hydroxocobalamin acetate is an injectable natural vitamin B12. Hydroxocobalamin acetate binds to NO. Hydroxocobalamin acetate detoxifies Cyanide and NaSH. Hydroxocobalamin acetate reduces hypotension. Hydroxocobalamin acetate is used in research related to vitamin B12 deficiency, including pernicious anemia .
    Hydroxocobalamin acetate
  • HY-P4070

    Insulin Receptor Metabolic Disease
    Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
    Insulin icodec
  • HY-N0267
    Hypaconitine
    2 Publications Verification

    NF-κB Potassium Channel Calcium Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Hypaconitine inhibits the KCNH2 current with an IC50 of 8.1 nM, and exhibits cardiotoxicity. Hypaconitine inhibits TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cell through the inhibition of NF-κB nuclear translocation. Hypaconitine acts as the neuromuscular blocker. Hypaconitine is orally active .
    Hypaconitine
  • HY-W243408C

    Limestone, 99%

    Environmental Pollutants Biochemical Assay Reagents Others
    Calcium carbonate, 99% (Limestone, 99%) is a calcium carbonate salt and also a mineral. Calcium carbonate, 99% serves as a thickener and acidity regulator .
    Calcium carbonate, 99%
  • HY-109968

    CEP-26401

    Histamine Receptor Neurological Disease Metabolic Disease
    Irdabisant (CEP-26401) is a selective, orally active and blood-brain barrier (BBB) penetrant histamine H3 receptor (H3R) inverse agonist/inverse agonist with Ki values of 7.2 nM and 2.0 nM for rat H3R and human H3R, respectively. Irdabisant has relatively low inhibitory activity against hERG current with an IC50 of 13.8 μM. Irdabisant has cognition-enhancing and wake-promoting activities in the rat social recognition model. Irdabisant can be used to research schizophrenia or cognitive impairment .
    Irdabisant
  • HY-126367
    Light green SF yellowish
    1 Publications Verification

    Acid Green 5

    Fluorescent Dye Cancer
    Light green SF yellowish (Acid Green 5) is a water-soluble triarylmethane dye. Light green SF yellowish serves as a histological stain that selectively labels mitochondria, collagen, and cartilage, while being an essential component of Papanicolaou staining. Light green SF yellowish is commonly used as a cytoplasmic counterstain for nuclear stains, and is applied in Masson's trichrome staining for collagen fibers, Pap staining, and cytological polychromatic staining in histopathology. Light green SF yellowish also induces growth inhibition and local fibrosarcomas in rats and exerts mild pulmonary tumorigenicity in mice .
    Light green SF yellowish
  • HY-W003467

    Drug Metabolite Bacterial Infection Inflammation/Immunology
    Rabeprazole Sulfide is a sulfide metabolite of Rabeprazole (HY-B0656). Rabeprazole Sulfide inhibits Helicobacter pylori motility. Rabeprazole Sulfide can be used for the research of Helicobacter pylori infection .
    Rabeprazole Sulfide
  • HY-155351

    PARP Cytochrome P450 Cancer
    PARP7-IN-15 is an orally active and selective PARP7 inhibitor with an IC50 of 0.56 nM. PARP7-IN-15 inhibits the enzymatic activity of PARP7 and induces anti-tumor activity against lung cancer in vivo. PARP7-IN-15 can be used for the research of lung cancer .
    PARP7-IN-15
  • HY-121144

    Refosporen

    Antibiotic Bacterial Infection
    Cefazedone (Refosporen) is a first-generation cephalosporin antibiotic. Cefazedone is active against both Gram-positive and Gram-negative bacteria .
    Cefazedone
  • HY-17549

    CRL 40028

    Adrenergic Receptor Neurological Disease
    Adrafinil (CRL 40028) is an orally active vigilance promoting agent. Adrafinil enhances central noradrenergic transmission, improves spontaneous activity, exploratory behavior, discriminative learning ability and response motivation, but impairs visuospatial working memory. Adrafinil antagonizes Prazosin (HY-B0193)-induced hypoactivity and hypothermia, exerts anticonvulsant effects, and induces sustained enhancement of high-frequency electrocortical activity. Adrafinil can be used for research on decreased alertness and specific cognitive deficits .
    Adrafinil
  • HY-B1017

    EN-1733A

    Dopamine Receptor Neurological Disease
    Molindone hydrochloride (EN-1733A) is an orally active and brain-penetrant dopamine D2/D5 receptor antagonist. Molindone hydrochloride shows antipsychotic and antidepressant-like activities. Molindone hydrochloride suppresses spontaneous locomotion, and antagonizes apomorphine-induced emesis. Molindone hydrochloride can be used for the research of neurological disease .
    Molindone hydrochloride
  • HY-N11857

    Antibiotic Bacterial Infection
    Gentamicin C2 is an aminoglycoside antibiotic with broad-spectrum bactericidal activity, selectively binding to the bacterial 16S rRNA A-site. Gentamicin C2 interferes with protein synthesis initiation and translation fidelity to exert bactericidal effects. Gentamicin C2 can be used for the research of bacterial infections .
    Gentamicin C2
  • HY-14157

    Opioid Receptor Inflammation/Immunology
    ADL-5747 is a selective and orally active agonist of the δ-opioid receptor (DOR). By binding to the δ-opioid receptors, ADL-5747 activates these receptors, thereby playing a role in pain management pathways. ADL-5747 can be used for research into pain management mechanisms .
    ADL-5747
  • HY-116691

    Hydrocortisone 17-propionate 21-acetate

    Glucocorticoid Receptor Neurological Disease Inflammation/Immunology
    Hydrocortisone aceponate (Hydrocortisone 17-propionate 21-acetate) is a diester-based topical glucocorticoid. Hydrocortisone aceponate alleviates symptoms such as erythema, dryness/desquamation, pruritus, epidermal exfoliation, and exudation/crusting. Hydrocortisone aceponate causes extremely few adverse reactions. Hydrocortisone aceponate is applicable to various dermatological disease studies .
    Hydrocortisone aceponate
  • HY-N9279

    Monocrotaline pyrrole; MCTP; 3,8-Didehydromonocrotaline

    Endogenous Metabolite Cardiovascular Disease Cancer
    Dehydromonocrotaline is a mitochondrial respiratory chain complex I NADH oxidase inhibitor, with a IC50 of 62.06 μM and a Ki of 8.1 μM in rats. Dehydromonocrotaline exerts non-competitive inhibitory effects by modifying cysteine thiol groups on complex I, and does not bind to the NADH-binding site. Dehydromonocrotaline dissipates mitochondrial membrane potential and reduces ATP levels. Dehydromonocrotaline can be used in studies related to hepatotoxicity, pulmonary hypertension and liver tumors .
    Dehydromonocrotaline
  • HY-W250721D

    Carboxy polymethylene

    Biochemical Assay Reagents Others
    Carbomer (Carboxy polymethylene) is an acrylic acid polymer, which can be used as a thickening agent. Carbomer provides a stable gel matrix, exhibits good heat, light and microbial contamination resistance. Carbomer facilitates the drug release and local application, which can be used in the pharmaceutical industry .
    Carbomer
  • HY-118995

    GHSR Endocrinology
    L-739943 is a potent, and orally active growth hormone (GH) secretagogue with an ED50 of 1 nM. L-739943 stimulates GH release in beagle dogs. L-739943 can be used for GH-related diseases research .
    L-739943
  • HY-100516

    UR-8880

    COX Cytochrome P450 Inflammation/Immunology
    Cimicoxib (UR-8880) is an orally active, blood-brain barrier-permeable COX-2 inhibitor that also exerts targeted inhibition on CYP2D15. It has an IC50 of 66 nM against hCOX-2, an IC50 of 1.6 μM against canine CYP2D15, and an IC50 of 0.056 μM against feline CYP2D15. By inhibiting the COX-2 pathway to reduce the production of thromboxane B2 and prostaglandin E2, Cimicoxib exerts antipyretic, anti-inflammatory and analgesic effects. Cimicoxib is metabolized by CYP2D15 to form demethyl-cimicoxib, undergoes glucuronidation via UDP-glucuronosyltransferases, and exhibits biphasic elimination kinetics in beagle dogs. Cimicoxib is widely used in studies of inflammatory diseases, osteoarthritis, and perioperative pain associated with orthopedic or soft tissue surgeries .
    Cimicoxib
  • HY-174380

    Dipeptidyl Peptidase Ser/Thr Protease Elastase Inflammation/Immunology
    DPP-1-IN-1 (Compound 14) is an orally active inhibitor of Cathepsin C (also known as Dipeptidyl peptidase I) with an IC50 of 5.31 nM. DPP-1-IN-1 can inhibit the activity of Cathepsin C downstream Neutrophil elastase in neutrophils. DPP-1-IN-1 can be used in the research of inflammatory diseases .
    DPP-1-IN-1
  • HY-113567

    FXR Metabolic Disease
    GSK2324 (Compd 1c) is a FXR agonist for diabetes study, with an EC50 of 120 nM. GSK2324 exhibits t1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively .
    GSK2324
  • HY-172672

    Orexin Receptor (OX Receptor) Neurological Disease
    Orexin 2 Receptor Agonist 3 (Compound 57) is an orally active and brain-penetrant orexin receptor type-2 (OX2) agonist (EC50: 2.5 nM). Orexin 2 Receptor Agonist 3 increases wakefulness in the orexin/ataxin-3 NT1 mouse model and healthy beagle dogs. Orexin 2 Receptor Agonist 3 can be used in the study of narcolepsy .
    Orexin 2 Receptor Agonist 3
  • HY-171835

    HIV HIV Protease Infection
    DPC 684 is a potent and selective HIV-1 protease inhibitor (IC90 = 5.7-40 nM, Ki = 0.021 nM). DPC 684 competitively inhibits HIV-1 protease and blocks viral polyprotein cleavage. DPC 684 has low protein binding and broad-spectrum inhibition against a variety of wild-type and mutant HIV-1 proteases. DPC 684 has low protein binding and broad-spectrum inhibition (IC90 = 1.9-6.3 nM). DPC 684 has research significance for HIV .
    DPC 684
  • HY-150080

    BMS-986180

    HIV HIV Integrase Infection
    GSK3739936 (BMS-986180) is a potent HIV-1 allosteric integrase inhibitor with an IC50 value of 11.1 nM and an EC50 value of 1.7 nM. GSK3739936 is also a weak CYP inhibitor (IC50>24.3 μM). GSK3739936 shows favorable pharmacokinetic property in preclinical species with rapid absorption, low to moderate clearance and excellent oral bioavailability .
    GSK3739936
  • HY-144074

    LRRK2 Neurological Disease
    LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC50 of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease .
    LRRK2-IN-4
  • HY-142090

    SK&F 93574

    Histamine Receptor Others
    Donetidine (SK&F 93574) is an antagonist for histamine H2 receptor, that promotes histamine release in beagle dog models .
    Donetidine
  • HY-122349

    L-12717

    Drug Derivative Others
    Lotrifen is a non-hormonal compound with abortifacient effects. Lotrifen is most effective when used on the 20th day of pregnancy in beagle and mongrel dogs .
    Lotrifen
  • HY-111018

    Calcium Channel Cardiovascular Disease
    FPL 62129 is an antagonist for calcium channel. FPL 62129 reduces blood pressure and total peripheral resistance, increases the cardiac contractility and cardiac output in anarsthetised beagle model. FPL 62129 also serves as a vasodilator and a direct decelerator .
    FPL 62129
  • HY-164010

    Histamine Receptor Dopamine Receptor Adrenergic Receptor Sigma Receptor Cardiovascular Disease Inflammation/Immunology
    SUN-1334H free base is an orally active inhibitor for histamine H1 receptor, with an IC50 of 20.3 nM and Ki of 9.7 nM. SUN-1334H free base inhibits histamine-induced contractions of isolated guinea-pig ileum with an IC50 of 0.198 μM. SUN-1334H free base inhibits histamine-induced bronchoconstriction in guinea pigs, histamine-induced skin wheals in beagle dogs, and ovalbumin-induced rhinitis in guinea pigs .
    SUN-1334H free base
  • HY-123429

    Antibiotic Infection
    CK0683A is a novel biaminourea antibiotic with antiplaque effects and demonstrated efficacy in experimental mouse dental disease models. A 12-week study in beagles compared its efficacy in terms of plaque and gingivitis reduction, staining potential, and safety. Dogs were selected as the study subjects because the onset and progression of canine periodontal disease is similar to that of humans. As a positive control for plaque and gingivitis reduction and staining, chlorhexidine acetate was selected because it is effective in both humans and dogs.
    CK0683A
  • HY-123479

    Antibiotic Infection
    CK0492B is a novel biaminourea antibiotic that has antiplaque properties in vitro and has shown efficacy in an experimental mouse dental disease model. A 12-week study in beagles compared its efficacy in reducing plaque and gingivitis, staining potential, and safety. Dogs were selected as the study subjects because the onset and progression of canine periodontal disease are similar to humans. Chlorhexidine acetate was selected as a positive control for plaque and gingivitis reduction and staining because it is effective in both humans and dogs.
    CK0492B
  • HY-126762

    Progesterone Receptor Endocrinology
    Fenprostalene is an analog of Dinoprost (PGF2α) (HY-12956) that is used in veterinary medicine to induce corpus luteum regression and blood Progesterone (HY-N0437) levels reduction in dogs. Fenprostalene is potent in ameliorating pyometra and inducing abortion .
    Fenprostalene
  • HY-149927

    Drug Derivative Cancer
    Antitumor agent-91 is a cyclic phosphate ester derivative with anticancer and anti-proliferative activities. Antitumor agent-91 has potential application in human castration resistant prostate cancer and pancreatic cancer .
    Antitumor agent-91
  • HY-B1573A

    AY-23,028; dl-Butaclamol hydrochloride

    Adrenergic Receptor Dopamine Receptor Neurological Disease
    (±)-Butaclamol hydrochloride (AY-23,028) is the antagonist for adrenergic receptor and dopamine receptor. (±)-Butaclamol hydrochloride antagonizes amphetamine or Apomorphine (HY-12723)-induced stereotyped behaviors and emesis, inhibits discriminative avoidance behavior, and induces catalepsy in rats models .
    (±)-Butaclamol hydrochloride
  • HY-161349

    Aminopeptidase Inflammation/Immunology
    LTA4H-IN-4 (compound 3) is an orally active LTA4H inhibitor. The IC50 value of LTA4H-IN-4 for hERG is 156 μM. LTA4H-IN-4 can be used in inflammation related studies .
    LTA4H-IN-4
  • HY-14157A

    Opioid Receptor Inflammation/Immunology
    ADL-5747 hydrochloride is a selective and orally active agonist of the δ-opioid receptor (DOR). By binding to the δ-opioid receptors, ADL-5747 hydrochloride activates these receptors, thereby playing a role in pain management pathways. ADL-5747 hydrochloride can be used for research into pain management mechanisms .
    ADL-5747 hydrochloride
  • HY-100516R

    UR-8880 (Standard)

    Reference Standards Cytochrome P450 COX Inflammation/Immunology
    Cimicoxib (Standard) is the analytical standard of Cimicoxib. This product is intended for research and analytical applications. Cimicoxib (UR-8880) is an orally active, blood-brain barrier-permeable COX-2 inhibitor that also exerts targeted inhibition on CYP2D15. It has an IC50 of 66 nM against hCOX-2, an IC50 of 1.6 μM against canine CYP2D15, and an IC50 of 0.056 μM against feline CYP2D15. By inhibiting the COX-2 pathway to reduce the production of thromboxane B2 and prostaglandin E2, Cimicoxib exerts antipyretic, anti-inflammatory and analgesic effects. Cimicoxib is metabolized by CYP2D15 to form demethyl-cimicoxib, undergoes glucuronidation via UDP-glucuronosyltransferases, and exhibits biphasic elimination kinetics in beagle dogs. Cimicoxib is widely used in studies of inflammatory diseases, osteoarthritis, and perioperative pain associated with orthopedic or soft tissue surgeries .
    Cimicoxib (Standard)
  • HY-111245

    Potassium Channel Calcium Channel Sodium Channel Cardiovascular Disease Neurological Disease
    AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research .
    AZD-1305
  • HY-14939A

    Histamine Receptor Inflammation/Immunology
    Vapitadine hydrochloride (Compound 3a) is a selective, orally active and nonsedating antihistamine agent, which exhibits a good binding affinity with human cloned histamine H1 receptor with a Ki of 19 nM. Vapitadine hydrochloride decreases the histamine-induced lethality (ED50 is 0.056-1.2 mg/kg), antagonizes the cutaneous reactions to histamine (ED50 is 0.51-1.4 mg/kg) in rats .
    Vapitadine hydrochloride
  • HY-109968A

    CEP-26401 hydrochloride

    Histamine Receptor Neurological Disease
    Irdabisant (CEP-26401) hydrochloride is a selective, orally active and blood-brain barrier (BBB) penetrant histamine H3 receptor (H3R) inverse agonist/inverse agonist with Ki values of 7.2 nM and 2.0 nM for rat H3R and human H3R, respectively. Irdabisant hydrochloride has relatively low inhibitory activity against hERG current with an IC50 of 13.8 μM. Irdabisant hydrochloride has cognition-enhancing and wake-promoting activities in the rat social recognition model. Irdabisant hydrochloride can be used to research schizophrenia or cognitive impairment .
    Irdabisant hydrochloride
  • HY-W423010

    Antibiotic Bacterial Infection
    Cefazedone (Refosporen) is a first-generation cephalosporin antibiotic. Cefazedone is active against both Gram-positive and Gram-negative bacteria .
    Cefazedone sodium
  • HY-183318

    PPAR Metabolic Disease
    PPARα/δ agonist 4 is a potent orally active and selective dual peroxisome proliferator-activated receptor (PPAR) α/δ agonist with EC50s of 0.36 and 1.31 nM, respectively. PPARα/δ agonist 4 exhibits >123-fold selectivity over PPARγ (EC50 = 160.84 nM). PPARα/δ agonist 4 upregulates expression of downstream fatty acid oxidation genes PDK4, CPT1A, and ACADVL. PPARα/δ agonist 4 can be used for the research of metabolic dysfunction-associated steatohepatitis .
    PPARα/δ agonist 4
  • HY-P11800

    MMP Inflammation/Immunology
    GPLGVRG is an MMP13-responsive linker peptide. GPLGVRG can be hydrolyzed by MMP13, which in turn triggers micellar disintegration, loss of amphipathicity, and increases the chondrocyte uptake rate of the related delivery system. GPLGVRG can be used in the research of osteoarthritis .
    GPLGVRG
  • HY-182320

    CETP Cardiovascular Disease
    DRL-17822 is a selective cholesteryl ester transfer protein (CETP) inhibitor. DRL-17822 increases high-density lipoprotein levels. The exposure of DRL-17822 nanocrystal formulation increases significantly after a high-fat breakfast. The exposure of DRL-17822 in the fasted state is higher than that of its nanocrystal formulation. DRL-17822 can be used in the research of type II hyperlipidemia and atherosclerotic cardiovascular disease .
    DRL-17822
  • HY-48813

    Endogenous Metabolite NF-κB Interleukin Related Metabolic Disease
    Glycoursodeoxycholic acid 3-sulfate is a glycine-conjugated sulfated bile acid 3-sulfate, which is produced by SULT2A1-mediated sulfation of glycoursodeoxycholic acid (HY-N1424) in the liver. Glycoursodeoxycholic acid 3-sulfate attenuates the anti-inflammatory effect of glycoursodeoxycholic acid and impairs the inhibitory effect on the IL-17 and NF-κB signaling pathways. Glycoursodeoxycholic acid 3-sulfate shows a significant correlation with aortic flow velocity and BNP in patients with aortic stenosis. Glycoursodeoxycholic acid 3-sulfate is mainly used in related studies such as quantitative analysis, quality control and biochemical experiments; it often serves as a reagent for metabolomics analysis and can also be applied to research related to aortic stenosis .
    Glycoursodeoxycholic acid 3-sulfate
  • HY-185643

    Prostaglandin Receptor Neurological Disease
    PF-04475270 is a prodrug of CP-734432 (HY-119236), as well as an agonist of the EP4 prostaglandin receptor, with IC50 values of 2 nM and 8 nM against human and canine sources, respectively. PF-04475270 is rapidly hydrolyzed into its active metabolite CP-734432 by ocular esterases or corneal homogenate, stimulates cAMP production, and activates cAMP response element-mediated β-lactamase activity in cells expressing EP4. PF-04475270 can be used in research related to glaucoma .
    PF-04475270
  • HY-17604
    Bexagliflozin
    1 Publications Verification

    EGT1442; EGT0001442; THR-1442

    SGLT Cardiovascular Disease Metabolic Disease
    Bexagliflozin (EGT1442) is an orally active and selective SGLT2 inhibitor with IC50 values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin reduces blood glucose and HbA1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin can be used for the research of type 2 diabetes mellitus, hypertensive stroke .
    Bexagliflozin
  • HY-119236

    CP-734432

    Prostaglandin Receptor Beta-lactamase Neurological Disease
    CP-432 (CP-734432) is a EP4 receptor agonist with an IC50 of 2 nM for human sources, 8 nM for canine sources, and an EC50 of 1 nM for human sources. CP-432 stimulates cAMP production and activates β-lactamase (β-lactamase) activity via the cAMP response element signaling pathway. CP-432 is applicable to research related to glaucoma .
    CP-432
  • HY-182386

    NKCC Metabolic Disease Endocrinology
    Triflocin is an orally active diuretic and Na +-K +-2Cl cotransporter inhibitor with an IC50 of 3×10 -5 M. Triflocin inhibits the outward basolateral electrogenic Na-(HCO3) n>1 cotransport in the proximal tubule. Triflocin has no tendency to induce hyperglycemia, and its blood glucose-elevating effect is extremely weak, such that an increase in blood glucose levels can only be detected under special conditions such as glucose loading. Triflocin is more prone to induce hypoglycemia .
    Triflocin
  • HY-182589

    FAAH Potassium Channel Neurological Disease Metabolic Disease
    SRP-001 is an orally active, blood-brain barrier-permeable analgesic and antipyretic agent. SRP-001 reduces the expression level of FAAH, mildly inhibits hERG currents, generates AM404 (HY-101388), and maintains the integrity of hepatic tight junctions. SRP-001 exerts analgesic, antipyretic, and antinociceptive effects .
    SRP-001
  • HY-182691

    HCV Infection
    Amphihevir is an orally active HCV NS4B inhibitor. Amphihevir exhibits activity against HCV genotype 1a and 1b replicons and reduces HCV RNA levels. Amphihevir can be used in the research of chronic hepatitis C .
    Amphihevir

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: